This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical siteSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyOff-contract claimsAlliance Healthcare

Example content

Menu

Close

About VTEAbout VTEVTE risk factors and NICE GuidanceVTE recurrence risk factors and NICE GuidanceNICE Guidance for treating VTE in cancer patientsAbout EliquisAbout EliquisLearn more about EliquisPatient information bookletsSupporting ResourcesPatient Support & ResourcesMaterialsVideos

Click here for Eliquis® (apixaban) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

VTE is a large clinical burden in the UK and Europe

Venous thromboembolism (VTE) is a condition in which a blood clot forms, most often in the deep veins of the leg, groin or arm (known as deep vein thrombosis, DVT). These clots may break free and travel in the blood, lodging in the lungs (known as pulmonary embolism, PE). Together, DVT and PE are known as venous thromboembolism (VTE) – a dangerous, and potentially fatal medical condition. Venous thromboembolism is a leading cause of death and disability worldwide.1
United Kingdom
  • Up to 1 in every 1,000 people are affected by a VTE each year2
  • Up to 55% of VTE cases occur during or after hospitalisation, making it a leading preventable cause of hospital death3
  • The average cost of VTE treatment and management was estimated at £1,011,437 per NHS Trust in 2017/18*4
 Button Loading

Click here for Eliquis® (apixaban) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Europe
Europe
  • In Europe, there are approximately 544,000 VTE-related deaths every year3
 Button Loading
Implementation of appropriate VTE prophylaxis is a high priority

VTE risk factors and NICE guildelines

Learn more about the risk factors for VTE and NICE guideline on VTE NG158 for DVT & PE.

Learn moreLoading
NICE guidelines for treating VTE in cancer patients

Find out more about the NICE recommendations for the treatment of VTE  in patients with cancer & factors to
consider when choosing anticoagulant treatment for such patients.

Discover moreLoadingOur brand - Eliquis (apixaban)

ELIQUIS – an oral, direct factor Xa inhibitor – is indicated for:

Treatment of DVT and PE, and prevention of recurrent DVT and PE in adults.
 

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II).

Explore EliquisLoading*Annual VTE-related costs are from the All-party Parliamentary Thrombosis Group freedom of information survey for 2016/17, which focused specifically on the cost of VTE treatment and management at CCG and Trust level and was responded to by 46% of CCGs.
  1. NHS Isle of Wight NHS Trust, 2021, Venous thromboembolism (VTE) Inpatient information leaflet. Available from:venous_thromboembolism_inpatient_v1.indd (iow.nhs.uk). Last accessed August 2023.
  2. Thrombosis UK. Venous Thrombosis. Available at: https://www.thrombosisuk.org/admin/resources/downloads/thrombosisuk-venous-thrombosis-leaflet.pdf. Last accessed April 2022.
  3. Thrombosis UK. Thrombosis Statistics. Available at: https://www.thrombosisuk.org/thrombosis-statistics.php. Last accessed April 2022.
  4. All-Party Parliamentary Thrombosis Group (APPTG). Annual Review & Survey Results November 2018. Available at: http://apptg.org.uk/wp-content/uploads/APPTG-annual-survey-report-2018-compressed.pdf. Last accessed April 2022.
PP-ELI-GBR-10849. April 2023

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store


Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2023 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-4885. May 2023
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

YesNo
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​